CRL · Earnings call · 2026Q2T · Full report

Operating Expense Trends

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-08-05 · Importance 57 · Surprise 48 · No source text

Unallocated corporate costs totaled $72 million, or 7.2% of revenue, versus 5.9% in the prior-year quarter. The increase primarily reflected $6 million of deferred-compensation-plan costs, equal to $0.10 per share, caused by market performance of plan assets. Full-year corporate costs are now expected to be approximately 6.0% of revenue versus the prior 5.5% outlook because of higher performance-based compensation. Lower corporate costs are expected to drive approximately 150 basis points of second-half operating-margin improvement, including favorable CEO-transition stock compensation and lower second-half fringe costs.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
net_incomepositiverealized+1.9%Gains of $19 million or $0.29 per share were realized in the second quarter from investments related to the deferred compensation plan and…
marginnegativerealized-1.3%Unallocated corporate costs totaled $72 million or 7.2% of revenue in the second quarter compared to 5.9% in the prior year period,…
marginpositiveprobable+0.8%Lower corporate costs are estimated to drive approximately 150 basis points of the second half margin improvement, with the balance from…
operating_incomenegativerealized-0.6%Unallocated corporate costs totaled $72 million or 7.2% of revenue in the second quarter compared to 5.9% in the prior year period,…
net_incomenegativeprobable—Gains of $19 million or $0.29 per share were realized in the second quarter from investments related to the deferred compensation plan and…